Teleflex (NYSE:TFX) Lowered to Buy Rating by Wall Street Zen

Key Points

• Teleflex has been downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, reflecting a more cautious outlook on the stock's performance.
• The company's latest quarterly earnings report showed an EPS of $3.73, surpassing analyst estimates of $3.36, with a revenue increase of 4.2% year-over-year.
• Recent insider transactions include Director Stuart A. Randle and CEO Liam Kelly purchasing shares, indicating confidence in the company's future performance.

Wall Street Zen lowered shares of Teleflex (NYSE:TFX - Free Report) from a strong-buy rating to a buy rating in a report released on Saturday morning.

A number of other analysts also recently issued reports on TFX. Truist Financial decreased their price objective on shares of Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a report on Monday, May 5th. Mizuho increased their target price on shares of Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a research report on Friday, August 1st. Morgan Stanley lowered their price target on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a report on Monday, May 5th. Wells Fargo & Company dropped their price objective on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Finally, Royal Bank Of Canada increased their price objective on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a report on Friday, August 1st. One analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $141.57.

Teleflex Stock Performance

Shares of NYSE TFX traded down $0.88 during midday trading on Friday, reaching $126.16. The company's stock had a trading volume of 287,301 shares, compared to its average volume of 779,420. The stock has a market capitalization of $5.58 billion, a P/E ratio of 29.67, a PEG ratio of 1.76 and a beta of 1.08. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The firm has a 50 day moving average price of $119.36 and a 200-day moving average price of $128.55. Teleflex has a 12-month low of $108.90 and a 12-month high of $249.90.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. During the same period last year, the company posted $3.42 earnings per share. Teleflex's quarterly revenue was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, equities analysts predict that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 15th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, August 15th. Teleflex's dividend payout ratio (DPR) is 32.00%.

Insider Activity at Teleflex

In other news, Director Stuart A. Randle purchased 1,000 shares of the firm's stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $115.86 per share, with a total value of $115,860.00. Following the completion of the acquisition, the director owned 7,547 shares in the company, valued at $874,395.42. This trade represents a 15.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Andrew A. Krakauer acquired 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average cost of $115.25 per share, with a total value of $115,250.00. Following the purchase, the director directly owned 7,192 shares of the company's stock, valued at $828,878. This trade represents a 16.15% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 5,500 shares of company stock valued at $633,590 in the last quarter. 1.40% of the stock is currently owned by company insiders.

Institutional Trading of Teleflex

Large investors have recently modified their holdings of the business. Thurston Springer Miller Herd & Titak Inc. raised its stake in Teleflex by 242.9% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company's stock valued at $26,000 after purchasing an additional 153 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Teleflex by 103.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock worth $27,000 after acquiring an additional 100 shares during the last quarter. Banque Cantonale Vaudoise purchased a new position in Teleflex in the first quarter worth $27,000. Costello Asset Management INC purchased a new position in Teleflex in the first quarter worth $28,000. Finally, Brooklyn Investment Group increased its stake in Teleflex by 258.6% in the first quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 150 shares during the last quarter. Institutional investors own 95.62% of the company's stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.